Highlight
– Long-term follow-up of 1202 multiple myeloma patients treated under early total therapy protocols demonstrated significant survival improvements.
– Incorporation of immunomodulatory drugs and proteasome inhibitors alongside tandem hematopoietic stem cell transplant increased 10-year progression-free survival from 9% to 44%.
– Median overall survival reached approximately 12 years in the most recent TT 3A protocol, with 15-year survival rates up to 40%.
– Low-risk gene expression profiling identified patients with even better long-term outcomes.
